拉米夫定、阿德福韦酯联合自体骨髓干细胞移植治疗乙肝肝硬化失代偿期患者的疗效观察  

Clinical efficacy of lamivudine,adefovir dipivoxil combined with autologous bone marrow stem cell transplantation in treatment of hepatitis B patients with decompensated liver cirrhosis

作　　者：刘黎[1] 周健[1] 黄丽雯[1] 何春萍[1] 周汉超[1] 

机构地区：[1]武汉科技大学附属天佑医院感染科,湖北武汉430064

出　　处：《胃肠病学和肝病学杂志》2011年第12期1092-1094,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的观察拉米夫定、阿德福韦酯联合自体骨髓干细胞移植治疗乙肝肝硬化失代偿期患者的临床效果。方法 77例乙肝肝硬化失代偿期患者随机分为两组。常规对症支持治疗方法下,A组(37例)采用拉米夫定、阿德福韦酯抗病毒治疗,B组(40例)在A组基础上加用自体骨髓干细胞移植治疗。治疗4周后复查各实验室指标、临床症状和体征情况。结果治疗4周后,B组血浆白蛋白、天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆红素水平、PT、AFP、胆碱酯酶等指标较A组明显改善(P<0.05);B组临床症状和体征较A组也明显改善(P<0.05)。结论采用拉米夫定、阿德福韦酯联合自体骨髓干细胞移植治疗乙肝肝硬化失代偿期患者,可有效避免骨髓干细胞受到患者体内乙肝病毒的感染和损害,帮助骨髓干细胞在肝脏环境内能分化为正常的肝细胞,参与肝脏结构的修复和重构,改善患者的肝功能,提高患者的生活质量。Objective To observe the clinical efficacy of lamivudine, adefovir dipivoxil combined with autologous bone marrow stem cell transplantation in treatment of hepatitis B patients with deeompensated liver cirrhosis. Methods 77 cases of hepatitis B patients with decompensated liver cirrhosis were randomly divided into two groups. Under the gen- eral treatment, A group （37 cases） were treated with lamivudine, adefovir dipivoxil for antiviral therapy, B group （40 cases） were treated with autologous bone marrow stem cell transplantation on the base of A group. The laboratory data, clinical symptoms and signs were observed after four weeks treatment. Results Four weeks after treatment, levels of al- bumin, AST, ALT, total bilirubin, PT, AFP and CHE were significantly improved compared with A group （P 〈 0.05）. The clinical symptoms and signs were significantly improved compared with A group （P 〈 0.05）. Conclusion The treatment of lamivudine, adefovir dipivoxil combined with autologous bone marrow stem cell transplantation on hepatitis B patients with decompensated liver cirrhosis could improve liver function.

关 键 词：拉米夫定 阿德福韦酯 自体骨髓干细胞 肝硬化失代偿期 

分 类 号：R575.2[医药卫生—消化系统]